预测肿瘤学公司2025年季度报告

FORM10-Q (Mark One) For the quarterly period endedSeptember 30, 2025 or☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________________________to _________________________ Commission File Number:001-36790 Predictive Oncology Inc.(Exact name of registrant as specified in its charter) Delaware33-1007393(State or other jurisdiction of(I.R.S. Employerincorporation or organization)Identification No.) 91 43rd Street, Suite 110Pittsburgh,Pennsylvania15201(Address of principal executive offices)(Zip Code) (412)432-1500(Registrant’s telephone number, including area code) (Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days.☒Yes☐No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files). ☒Yes☐No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smallerreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☐ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐Yes☒No As of November 10, 2025, the registrant had3,393,516shares of common stock, par value $0.01 per share outstanding. PREDICTIVE ONCOLOGY INC. TABLE OF CONTENTS PART I. FINANCIAL INFORMATIONITEM 1.UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS4CONDENSEDCONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER 30,2025 ANDDECEMBER 31, 20244CONDENSED CONSOLIDATED STATEMENTS OF NET LOSS FOR THE THREE AND NINEMONTHS ENDED SEPTEMBER 30, 2025 AND 20245CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’EQUITY (DEFICIT) FORTHE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 20246CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHSENDED SEPTEMBER 30, 2025 AND 20248NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS9ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ANDRESULTSOF OPERATIONS25ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK36ITEM 4. CONTROLS AND PROCEDURES36PART II. OTHER INFORMATION36ITEM 1. LEGAL PROCEEDINGS36ITEM 1A. RISK FACTORS37ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS48ITEM 3. DEFAULTS UPON SENIOR SECURITIES48ITEM 4. MINE SAFETY DISCLOSURES48ITEM 5. OTHER INFORMATION48ITEM 6. EXHIBITS49SIGNATURES50 ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS PREDICTIVE ONCOLOGY INC.CONDENSED CONSOLIDATED BALANCE SHEETS(Unaudited) PREDICTIVE ONCOLOGY INC.CONDENSED CONSOLIDATED STATEMENTS OF NET LOSS(Unaudited) PREDICTIVE ONCOLOGY INC.CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’EQUITY (DEFICIT)FOR THE THREE AND NINE MONTHS ENDEDSEPTEMBER 30, 2025(Unaudited) PREDICTIVE ONCOLOGY INC.CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’EQUITYFOR THE THREE AND NINE MONTHS ENDEDSEPTEMBER 30, 2024(Unaudited) PREDICTIVE ONCOLOGY INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited) PREDICTIVE ONCOLOGY INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited) NOTE 1–ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations Predictive Oncology Inc. (“Predictive Oncology” or the “Company”) is a knowledge-driven company focused on applyingartificial intelligence (“AI”) to support the discovery and development of optimal cancer therapies, which can ultimately lead tomore effective treatments and improved patient outcomes. Predictive Oncology uses AI and its proprietary biobank of150,000+tumor samples, categorized by tumor type, to provide actionable insights about drug compounds to improve the drug discoveryprocess and increase the probability of drug compound success. The Company also creates and develops tumor-specific 3D cellculture models mimicking the physiological environment of human tissue, enabling better-informed decision-making